We’re excited to keep you up to date on our activities through announcements, but you can also follow us on our social media channels to hear the latest news as it happens.
  
5 Sept 2025Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension
17 Mar 2025US FDA removes REMS requirement for TRYVIO (aprocitentan) –minimizing the burden on the healthcare delivery systems and patients
15 Nov 2024Idorsia’s once-daily TRYVIOTM (aprocitentan) is now available in the
U.S., advancing treatment options for millions of patients with
difficult-to-control hypertension
20 Mar 2024US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
10 Jun 2023Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS
10 May 2023Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic Stress Disorder (PTSD)
04 Apr 2023Idorsia Files Petition with the Drug Enforcement Administration (DEA) Urging Them to De-Schedule Dual Orexin Receptor Antagonist Class of Insomnia Medications
29 Nov 2022                Insomnia Extends Beyond the Bedroom: Survey Finds That Trouble Sleeping Can Lead to Rocky Relationships
09 Nov 2022Idorsia Announces its Insomnia Medication, QUVIVIQ (daridorexant), is now Covered by TRICARE
19 Jul 2022Idorsia Announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as Patient Ambassador for QUVIVIQ™ (daridorexant), a Once Nightly Treatment for Insomnia
06 Jun 2022SLEEP 2022: Idorsia U.S. to present data from Wake Up America survey, revealing the hidden toll of insomnia, along with three other abstracts on the evaluation and treatment of insomnia
23 May 2022Idorsia Announces Esteemed Actor, Author and Father, Taye Diggs, as Patient Ambassador for QUVIVIQ™ (daridorexant), a Once Nightly Treatment for Insomnia
13 May 2022Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Services Provider
02 May 2022Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
05 Apr 2022Results Announced from Largest U.S. Survey of People with Trouble Sleeping, as well as Doctors, to Better Understand the Hidden Toll of Insomnia
16 Mar 2022World Premiere: The Quest for Sleep, a Film Narrated by Octavia Spencer, Explores People’s Struggles with Insomnia and the Fascinating Science Behind How and Why We Sleep
20 Jan 2022The Lancet Neurology reports impact of daridorexant in insomnia
12 Jan 2022Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep
10 Jan 2022Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
17 Nov 2021Idorsia Convenes The Alliance for Sleep, a Force for Innovation and Change in the Insomnia Space